Curis | CRIS - Net Income


Curis reported $19.36M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Alaunos Therapeutics USD -1.16M 108K Sep/2025
Amgen USD 1.82B 486M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
Bayer EUR -3.76B 2.79B Dec/2025
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
CSL USD 401M 96.5M Dec/2025
Curis USD 19.36M 31.16M Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Exelixis USD 244.53M 50.95M Dec/2025
Gilead Sciences USD 2.18B 869M Dec/2025
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Incyte USD 303.33M 4.05M Mar/2026
Merck USD -4.24B 7.2B Mar/2026
Novartis USD 3.16B 747M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR 1.61B 2.42B Mar/2026
Takeda JPY 103.64B 115.44B Dec/2025
TG Therapeutics USD 23.04M 367.86M Dec/2025
Verastem USD -32.92M 24.66M Dec/2025
Xoma USD -17.24M 33.23M Sep/2024